2022
Reliability of patient self-reports to clinician-assigned functional scores of inclusion body myositis
Roy B, Zubair A, Petschke K, O'Connor KC, Paltiel AD, Nowak RJ. Reliability of patient self-reports to clinician-assigned functional scores of inclusion body myositis. Journal Of The Neurological Sciences 2022, 436: 120228. PMID: 35344793, DOI: 10.1016/j.jns.2022.120228.Peer-Reviewed Original ResearchConceptsIBM functional rating scaleInclusion body myositisBody myositisInterrater correlation coefficientSporadic inclusion body myositisFine motor skillsImpaired ambulationFleiss kappa statisticFunctional scoresHand functionDisease progressionWhite CaucasiansClinical practiceNatural history dataRating ScaleKappa statisticsMyositisScoresMotor skillsIndividual questionsSubstantial agreementCorrelation coefficient analysisReliable indicatorParticipantsAmbulation
2021
Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021
Paltiel AD, Schwartz JL. Assessing COVID-19 Prevention Strategies to Permit the Safe Opening of Residential Colleges in Fall 2021. Annals Of Internal Medicine 2021, 174: m21-2965. PMID: 34461034, PMCID: PMC8422997, DOI: 10.7326/m21-2965.Peer-Reviewed Original ResearchConceptsVaccine effectivenessVaccination coverageAsymptomatic testingBroad vaccination coverageLess frequent testingCOVID-19 prevention strategiesHigh vaccination ratesBase-case assumptionsFall 2021COVID-19 incidenceUnvaccinated personsVaccination ratesDisease progressionHypothetical cohortEffective vaccineAsymptomatic transmissionPrevention strategiesViral transmissionCumulative casesNonpharmaceutical interventionsDrug abuseCumulative infectionsSafe returnVaccinePopulation coverageClinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission.
Paltiel AD, Zheng A, Sax PE. Clinical and Economic Effects of Widespread Rapid Testing to Decrease SARS-CoV-2 Transmission. Annals Of Internal Medicine 2021, 174: 803-810. PMID: 33683930, PMCID: PMC9317280, DOI: 10.7326/m21-0510.Peer-Reviewed Original ResearchConceptsSARS-CoV-2Antigen testingHome testingSARS-CoV-2 antigen testingIncremental cost-effectiveness ratioSARS-CoV-2 transmissionCost-effectiveness ratioBase-case analysisRapid testingPrevention guidanceDeath avertedDisease progressionInpatient careCommunity transmissionOutcome estimatesTesting interventionsViral transmissionDisease controlInfectionNumber of personsCumulative infectionsNational containment strategyWarrants considerationU.S. populationDeath
2017
The Inclusion Body Myositis Registry at Yale: A growing information database and practical tool for researchers, clinicians, and patients
Cotzomi E, Petschke K, O'Connor K, Paltiel A. The Inclusion Body Myositis Registry at Yale: A growing information database and practical tool for researchers, clinicians, and patients. Muscle & Nerve 2017 DOI: 10.1002/mus.25774.Peer-Reviewed Original Research
2015
Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration
Losina E, Michl G, Collins JE, Hunter DJ, Jordan JM, Yelin E, Paltiel AD, Katz JN. Model-based evaluation of cost-effectiveness of nerve growth factor inhibitors in knee osteoarthritis: impact of drug cost, toxicity, and means of administration. Osteoarthritis And Cartilage 2015, 24: 776-785. PMID: 26746146, PMCID: PMC4838505, DOI: 10.1016/j.joca.2015.12.011.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAnti-Inflammatory Agents, Non-SteroidalCost-Benefit AnalysisDisease ProgressionDrug CostsFemaleHealth Care CostsHealth Services ResearchHumansInfusions, IntravenousInjections, SubcutaneousMaleMiddle AgedModels, EconometricNerve Growth FactorOsteoarthritis, KneePain MeasurementQuality-Adjusted Life YearsSelf AdministrationUnited StatesConceptsNerve growth factor inhibitorsQuality-adjusted life yearsStandard of careTotal knee replacement surgeryIncremental cost-effectiveness ratioGrowth factor inhibitorsKnee osteoarthritisFactor inhibitorsOA progressionSelf-administered subcutaneous injectionsSevere knee osteoarthritisDirect medical costsKnee replacement surgeryQuality-adjusted life expectancyOsteoarthritis Policy ModelCost-effectiveness ratioMeans of administrationBase-case analysisCost-effective treatmentHospital deliveryIntravenous infusionDisease progressionLifetime riskReplacement surgerySubcutaneous injection
2004
A therapeutic HIV vaccine: how good is good enough?
Walensky RP, Paltiel AD, Goldie SJ, Gandhi RT, Weinstein MC, Seage GR, Smith HE, Zhang H, Freedberg KA. A therapeutic HIV vaccine: how good is good enough? Vaccine 2004, 22: 4044-4053. PMID: 15364455, DOI: 10.1016/j.vaccine.2004.03.059.Peer-Reviewed Original Research
2001
Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus
Paltiel A, Goldie S, Losina E, Weinstein M, Seage G, Kimmel A, Zhang H, Freedberg K. Preevaluation of Clinical Trial Data: The Case of Preemptive Cytomegalovirus Therapy in Patients with Human Immunodeficiency Virus. Clinical Infectious Diseases 2001, 32: 783-793. PMID: 11229847, DOI: 10.1086/319223.Peer-Reviewed Original ResearchMeSH KeywordsAIDS-Related Opportunistic InfectionsAntiviral AgentsChemopreventionCost-Benefit AnalysisCytomegalovirusCytomegalovirus InfectionsGanciclovirHIV InfectionsHumansModels, BiologicalPolymerase Chain ReactionPredictive Value of TestsQuality-Adjusted Life YearsSensitivity and SpecificityValganciclovirConceptsHuman immunodeficiency virusDuration of survivalPreemptive therapyCMV casesImmunodeficiency virusCMV polymerase chain reactionEnd-stage HIV diseaseUpcoming trialsCMV preemptive therapySalvage antiretroviral therapyCells/microLClinical trial dataCMV prophylaxisAntiretroviral therapyHIV diseaseComplication rateEfficacy assumptionsPolymerase chain reactionDisease progressionClinical uncertaintyDrug effectsPatientsTrial dataTherapyChain reaction